viernes, 13 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 12, 2026

Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference

View original at finance.yahoo.com
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference Legend Biotech USA Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The latest NCCN guidelines recommend talquetamab as a bridging therapy before CAR-T treatment for people with relapsed/refractory multiple myeloma to help keep patients eligible for CARVYKTI and improve outcomes

    80% confidence

  • Patients treated earlier, after one or two prior lines of therapy, exhibited greater immune fitness and a more immunocompetent tumor microenvironment, potential biological indicators of longer progression-free survival

    80% confidence

  • CARVYKTI cemented its status as the undisputed leader in multiple myeloma CAR-T cell therapy, with its continued record-breaking performance culminating in the achievement of more than 10,000 patients treated earlier this year

    80% confidence

  • We're also committed to leveraging our proven CAR-T development platform to frontline multiple myeloma and promising new in vivo and allogeneic opportunities to extend our leadership in cell therapy innovation

    80% confidence

  • Targeting multiple investigational new drug (IND) filings for oncology and autoimmune indications starting in second half 2026

    80% confidence

  • The Company believes cash and cash equivalents, and time deposits of approximately $1.0 billion as of September 30, 2025, will provide financial runway beyond 2026

    80% confidence

  • Triple-class-exposed patients treated with three prior lines of therapy from the CARTITUDE-1 and CARTITUDE-4 trials achieved a median progression-free survival of 50.4 months following a single infusion of CARVYKTI

    80% confidence

  • Anticipate CARVYKTI franchise FY 2025 profitability

    80% confidence

  • First-in-human data for in vivo dual CD20/CD19 therapy expected starting in the second half of 2026

    80% confidence

  • Legend Biotech is poised for transformative growth in 2026, as we work to achieve profitability this year by driving global adoption of CARVYKTI

    80% confidence

  • Expect company-wide operating profit in 2026

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,995
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,995 hechos verificados con la fuente5,577 documentos fuente archivados
Consulta estos datos → isubstrate.com
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference — Source | Via News | es.VIA.NEWS